As Chinese biotech and pharmaceutical innovation accelerates, many companies are taking the next step, expanding clinical development into Europe. The European Union (EU) offers access to a large patient population, world-class research infrastructure, and a harmonized regulatory system under the EU Clinical Trials Regulation (EU CTR 536/2014).
However, this opportunity also comes with complexity. Sponsors entering Europe for the first time must adapt to new documentation formats, ethics review structures, data protection obligations, and supply chain requirements, all while maintaining compliance across multiple jurisdictions.
To help guide sponsors through this process, our eight-part blog series, “Regulatory Challenges for Chinese Biotech Expanding Trials to Europe”, breaks down the most critical regulatory topics that impact clinical trial success under the EU CTR framework.
In this series, we explore:
- Understanding and Applying EU CTR – Key principles for navigating the EU’s unified clinical trial system.
- Bridging Regulatory Systems – How to adapt from China’s IND process to Europe’s CTA model.
- From Data to Compliance – Building an EU-compliant IMPD and CTA dossier.
- Ethics Review and Localization – Managing multinational submissions and language requirements.
- Data Protection under GDPR – Ensuring lawful data processing and cross-border compliance.
- IMP Release and Supply Management – Meeting EU GMP, GDP, and Qualified Person (QP) obligations.
- Pharmacovigilance and Safety Reporting – Establishing compliant safety and EudraVigilance systems.
- Country-Specific Differences and Local Strategies – Navigating variations among EU Member States.
Why This Matters
For Chinese sponsors, mastering the EU regulatory environment is not just about meeting compliance, it’s about building global credibility, accelerating access to patients, and strengthening long-term development capability.
Through practical insights and cross-border regulatory expertise, this series aims to help sponsors translate regulatory complexity into strategic advantage.
Next Article: Understanding and Applying EU CTR: Navigating Successful Clinical Trial Submissions